Held by 3 specialist biotech funds
High Convergence**SIGNAL NOTE: Driehaus Capital Initiates $34.4M Position in Travere Therapeutics** Growth-focused Driehaus is backing Travere's late-stage pipeline, likely positioning for near-term catalysts around IgA nephropathy (PROTECT studies readout expected 2024-2025) and other rare kidney disease programs where the company holds meaningful IP.
AI analyst context — unlock full analysis
# Signal Note: Perceptive Advisors Initiates $163.5M Position in Travere Therapeutics Edelman's new 4.3M share stake in TVTX signals conviction in Travere's clinical pipeline, likely centered on the company's late-stage programs in rare kidney diseases where unmet medical need and limited competition support premium pricing. The $163.5M position size reflects confidence in near-term catalysts, potentially including upcoming Phase 3 readouts or FDA decisions on lead candidates targeting IgA nephropathy and other glomerular diseases. Perceptive's entry merits monitoring given Edelman's track record with clinical-stage assets and Travere's regulatory pathway visibility into 2024-2025.
+ 1more — see how much conviction went in
See the Full Story